IL17A and arthritic joint disease: The resulting arthritis could be partially blocked with monoclonal antibodies against IL-17A and IL-22 and appeared to involve an enthesis-resident IL-23 receptor expressing CD3+CD4−CD8− T cell population, which produced IL-17A and IL-22 when stimulated with IL-23 in vitro [17].